Immunic, Inc. (IMUX)
Market price: $7.98
1 valuation method
- P / B: $17.99 to $43.97 (midpoint $26.91)
How each method works
P / B: $17.99 to $43.97 (midpoint $26.91)
Values the stock at a peer multiple of its book (net asset) value — most meaningful for asset-heavy and financial companies whose balance sheet drives value.
- How it’s calculated
- We take book value per share (total assets minus total liabilities, from the latest balance sheet, divided by shares outstanding) and multiply it by the range of price-to-book multiples the peer group trades at.
- Why it fits this industry
- Where the balance sheet is the business — lenders, insurers, asset-heavy operators — the price the market pays for a dollar of net assets is a natural yardstick.
- Reading this bar
- The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together. Asset-light companies (brands, software) legitimately trade far above book value, so for them a P/B bar well below the price is usually structure, not signal.
P / B = (1.92/2.88/4.70)× book_value_per_share 9.35 ≈ 17.99/26.91/43.97 (per_share)
6 methods not shown
- EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
- EV / Revenue: revenue unavailable — cannot form EV / Revenue
- EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
- P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
- DCF (FCFF): DCF input(s) unavailable (revenue_cagr) — cannot build FCFF
- P / E — adjusted: overlay rule suppressed the 'earnings_based' category for this company
Pre-profit company — earnings-based methods not meaningful.
Limited data — fewer than three valuation methods could be formed for this company; showing every method we can stand behind.